AU2015289524A1 - Toxic RNA inhibitors self-assembled in situ - Google Patents

Toxic RNA inhibitors self-assembled in situ Download PDF

Info

Publication number
AU2015289524A1
AU2015289524A1 AU2015289524A AU2015289524A AU2015289524A1 AU 2015289524 A1 AU2015289524 A1 AU 2015289524A1 AU 2015289524 A AU2015289524 A AU 2015289524A AU 2015289524 A AU2015289524 A AU 2015289524A AU 2015289524 A1 AU2015289524 A1 AU 2015289524A1
Authority
AU
Australia
Prior art keywords
rna
cell
modulator
permeable
k4nmes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015289524A
Other languages
English (en)
Inventor
Matthew D. Disney
Suzanne G. Rzuczek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of AU2015289524A1 publication Critical patent/AU2015289524A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2015289524A 2014-07-18 2015-07-17 Toxic RNA inhibitors self-assembled in situ Abandoned AU2015289524A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462026266P 2014-07-18 2014-07-18
US62/026,266 2014-07-18
PCT/US2015/040902 WO2016011348A1 (en) 2014-07-18 2015-07-17 Toxic rna inhibitors self-assembled in situ

Publications (1)

Publication Number Publication Date
AU2015289524A1 true AU2015289524A1 (en) 2017-02-02

Family

ID=55079084

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015289524A Abandoned AU2015289524A1 (en) 2014-07-18 2015-07-17 Toxic RNA inhibitors self-assembled in situ

Country Status (9)

Country Link
US (2) US10220031B2 (enExample)
EP (1) EP3169404A4 (enExample)
JP (2) JP6461306B2 (enExample)
CN (1) CN106714908A (enExample)
AU (1) AU2015289524A1 (enExample)
CA (1) CA2955428A1 (enExample)
IL (1) IL250113A0 (enExample)
SG (1) SG11201700387QA (enExample)
WO (1) WO2016011348A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015289524A1 (en) * 2014-07-18 2017-02-02 The Scripps Research Institute Toxic RNA inhibitors self-assembled in situ
WO2018098297A1 (en) * 2016-11-28 2018-05-31 The Scripps Research Institute Precise small molecule recognition of a toxic cug rna repeat expansion
SG11202003664TA (en) 2017-11-30 2020-05-28 Arrakis Therapeutics Inc Nucleic acid-binding photoprobes and uses thereof
AU2021336880A1 (en) * 2020-09-02 2023-04-13 Promega Corporation Nucleic acid modifying reagents and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008103489A2 (en) * 2007-02-23 2008-08-28 The Research Foundation Of State University Of New York Rna targeting compounds and methods for making and using same
WO2012050896A2 (en) * 2010-09-29 2012-04-19 Kansas State University Research Foundation Protease selective supramolecular assemblies
WO2012092367A1 (en) * 2010-12-28 2012-07-05 University Of Rochester Nucleic acid binding compounds, methods of making, and use thereof
CA2907072A1 (en) * 2012-03-16 2013-09-19 Valerion Therapeutics, Llc Antisense conjugates for decreasing expression of dmpk
CA2883320A1 (en) * 2012-08-30 2014-03-06 The Scripps Research Institute Small molecules targeting repeat r(cgg) sequences
AU2015289524A1 (en) * 2014-07-18 2017-02-02 The Scripps Research Institute Toxic RNA inhibitors self-assembled in situ

Also Published As

Publication number Publication date
CN106714908A (zh) 2017-05-24
SG11201700387QA (en) 2017-02-27
US10471057B2 (en) 2019-11-12
EP3169404A4 (en) 2018-02-07
WO2016011348A1 (en) 2016-01-21
JP2017522323A (ja) 2017-08-10
EP3169404A1 (en) 2017-05-24
US10220031B2 (en) 2019-03-05
US20190151310A1 (en) 2019-05-23
US20170143703A1 (en) 2017-05-25
CA2955428A1 (en) 2016-01-21
JP6461306B2 (ja) 2019-01-30
IL250113A0 (en) 2017-03-30
JP2019068831A (ja) 2019-05-09

Similar Documents

Publication Publication Date Title
US10471057B2 (en) Toxic RNA inhibitors self-assembled in situ
EP3022219B1 (en) Specific targeting of rna expanded repeat sequences
EP3038637B1 (en) Modularly assembled small molecules for the treatment of myotonic dystrophy type 1
Disney et al. Using selection to identify and chemical microarray to study the RNA internal loops recognized by 6′‐N‐acylated kanamycin A
Towbin et al. Systematic screens of proteins binding to synthetic microRNA precursors
Disney Rational design of chemical genetic probes of RNA function and lead therapeutics targeting repeating transcripts
Dimitrova-Paternoga et al. Validation and classification of RNA binding proteins identified by mRNA interactome capture
US10233442B2 (en) Method for affinity purification
US20080188377A1 (en) Methods for identifying ligands that target nucleic acid molecules and nucleic acid structural motifs
US9260476B2 (en) RNA targeting compounds and methods for making and using same
Tan et al. Label-free fluorescent assays based on aptamer–target recognition
US20220073910A1 (en) A Cross-Linking Approach to Map Small Molecule-RNA Binding Sites in Cells
CN103361337A (zh) 用于选择性制备生物学样品的胺化合物
Hasegawa et al. Context-dependent fluorescence detection of a phosphorylated tyrosine residue by a ribonucleopeptide
Steger et al. Functionalized polystyrene supports for solid-phase synthesis of glycyl-, alanyl-, and isoleucyl-RNA conjugates as hydrolysis-resistant mimics of peptidyl-tRNAs
HK1232823A1 (en) Toxic rna inhibitors self-assembled in situ
Peralta et al. Molecular recognition of HIV-1 RNAs with branched peptides
Johansson et al. Design, synthesis and ribosome binding of chloramphenicol nucleotide and intercalator conjugates
CN110408620A (zh) 一种核酸适配子、其获得方法、其衍生物及其应用
Phillips Biological Activity of a Py-Im Polyamide Androgen Receptor Antagonist
Sachdeva Deoxyribozymes for peptide substrates: Exploring the landscape of nucleophiles and electrophiles

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted